

# **Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update**

<https://marketpublishers.com/r/G39FC44B63D2EN.html>

Date: March 2022

Pages: 62

Price: US\$ 2,000.00 (Single User License)

ID: G39FC44B63D2EN

## **Abstracts**

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### **SUMMARY**

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Granulomatosis with Polyangiitis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Granulomatosis with Polyangiitis (Immunology) pipeline landscape.

Wegener Polyangiitis is an uncommon disorder that causes inflammation of blood vessels. This inflammation restricts blood flow to various organs. Signs and symptoms include constantly runny nose, nose bleeds, ear infections, cough, chest pain, skin sores and fever. Predisposing factor includes age. Treatment includes immunosuppressive and corticosteroids.

### **REPORT HIGHLIGHTS**

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Granulomatosis with Polyangiitis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Granulomatosis with Polyangiitis (Immunology), complete with analysis by stage of development, drug target, mechanism of action

(MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Granulomatosis with Polyangiitis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 3, 3, 2 and 3 respectively.

Granulomatosis with Polyangiitis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Granulomatosis with Polyangiitis (Immunology).

The pipeline guide reviews pipeline therapeutics for Granulomatosis with Polyangiitis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Granulomatosis with Polyangiitis (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Granulomatosis with Polyangiitis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Granulomatosis with Polyangiitis (Immunology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Granulomatosis with Polyangiitis (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Granulomatosis with Polyangiitis (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Overview

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Therapeutics

Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Therapeutics

Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Companies Involved in  
Therapeutics Development

Biogen Inc

Bristol-Myers Squibb Co

Chugai Pharmaceutical Co Ltd

GlaxoSmithKline Plc

iBio Inc

Iltoo Pharma

InflaRx NV

Kyowa Kirin Co Ltd

Mabion SA

Nanolek

Nichi-Iko Pharmaceutical Co Ltd

Nippon Shinyaku Co Ltd

Pharmapraxis

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Drug Profiles

abatacept - Drug Profile

Product Description

Mechanism Of Action

History of Events

aldesleukin - Drug Profile

Product Description

Mechanism Of Action

History of Events  
benralizumab - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
depemokimab - Drug Profile  
Product Description  
Mechanism Of Action  
mepolizumab - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
NS-229 - Drug Profile  
Product Description  
Mechanism Of Action  
rituximab - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
rituximab biobetter - Drug Profile  
Product Description  
Mechanism Of Action  
rituximab biosimilar - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
rituximab biosimilar - Drug Profile  
Product Description  
Mechanism Of Action  
rituximab biosimilar - Drug Profile  
Product Description  
Mechanism Of Action  
rituximab biosimilar - Drug Profile  
Product Description  
Mechanism Of Action  
tocilizumab - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events

vilobelimab - Drug Profile

Product Description

Mechanism Of Action

History of Events

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Dormant Projects

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Discontinued Products

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Product Development Milestones

Featured News & Press Releases

Oct 29, 2020: GSK Nucala (mepolizumab) filings accepted by European Medicines Agency for three additional eosinophil-driven diseases

Jan 30, 2020: The CHMP recommended extensions of indication for MabThera

Oct 09, 2019: Two new options for self-administration of NUCALA now approved in Canada, making it the first anti-IL5 biologic to offer patients with severe eosinophilic asthma a choice of how and where to receive treatment

Sep 30, 2019: Roche's Rituxan secures approval for first paediatric indication

Jun 12, 2019: FDA grants priority review to Genentech's Rituxan (Rituximab) in children with two rare blood vessel disorders

May 16, 2019: GSK presents Nucala at ATS 2019

Nov 27, 2018: FDA grants ODD for AstraZeneca's Fasenra to treat EGPA

Nov 15, 2018: Roche receives positive CHMP opinion to expand MabThera for the treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Dec 12, 2017: GSK Achieves Approval for Nucala (mepolizumab) for the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) for Adults in the US

Jun 28, 2017: GSK announces US regulatory submission for mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Mar 25, 2014: NICE says yes to new treatment for rare autoimmune disease in final guidance

Feb 14, 2014: GSK announces start of Phase III study for mepolizumab in patients with Eosinophilic Granulomatosis with Polyangiitis

Mar 22, 2013: Roche Receives CHMP Positive Opinion For MabThera

Apr 19, 2011: Genentech Receives FDA Approval For Rituxan Plus Steroid For Use In Severe Forms Of Vasculitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

[Contact Us](#)  
[Disclaimer](#)



## List Of Tables

### LIST OF TABLES

- Number of Products under Development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis), 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Biogen Inc, 2022
- Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Bristol-Myers Squibb Co, 2022
- Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Chugai Pharmaceutical Co Ltd, 2022
- Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by GlaxoSmithKline Plc, 2022
- Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by iBio Inc, 2022
- Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Ilto Pharma, 2022
- Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by InflaRx NV, 2022
- Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Kyowa Kirin Co Ltd, 2022
- Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Mabion SA, 2022
- Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Nanolek, 2022
- Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Nichi-Iko Pharmaceutical Co Ltd, 2022
- Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Nippon Shinyaku Co Ltd, 2022
- Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Pharmapraxi, 2022
- Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Dormant Projects, 2022

## Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis), 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

## I would like to order

Product name: Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/G39FC44B63D2EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G39FC44B63D2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

